Correction to: Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study

Rouzé, Anahita; Martín‐Loeches, Ignacio; Póvoa, Pedro; Makris, Demosthènes; Artigas, Antonio; Bouchereau, Mathilde; Lambiotte, Fabien; Metzelard, Matthieu; Cuchet, Pierre; Geronimi, Claire Boulle; Labruyère, Marie; Tamion, Fabienne; Nyunga, Martine; Luyt, Charles‐Édouard; Labreuche, Julien; Pouly, Olivier; Bardin, J. L.; Saade, Anastasia; Asfar, Pierre; Baudel, Jean-Luc; Beurton, Alexandra; Garot, Denis; Ioannidou, Iliana; Kreitmann, Louis; Llitjos, Jean-François; Magira, Eleni; Mégarbane, Bruno; Meguerditchian, David; Moglia, Edgar; Mekontso-Dessap, Armand; Reignier, Jean; Turpin, Matthieu; Pierre, Alexandre; Plantefève, Gaëtan; Vinsonneau, Christophe; Floch, Pierre-Edouard; Weiss, Nicolas; Ceccato, Adrián; Torres, Antoni; Duhamel, Alain; Nseir, Saad; Preau, Sébastien; Jourdain, M.; Poissy, Julien; Bouras, Chaouki; Leger, Piehr Saint; Fodil, Hanane; Aptel, François; Linden, Thierry Van Der; Thille, Arnaud W.; Azoulay, Élie; Pène, Frédéric; Razazi, Keyvan; Bagate, François; Contou, Damien; Voiriot, Guillaume; Thévenin, Didier; Guidet, Bertrand; Guennec, Loïc Le; Kouatchet, Achille; Ehrmann, Stéphan; Brunin, Guillaume; Morawiec, Élise; Boyer, Alexandre; Argaud, Laurent; Voicu, Sébastian; Nieszkowska, Ania; Kowalski, Benjamin; Gomà, Gemma; Dı́az, Emilio Moyano; Morales, Luis; Tsolaki, Vasiliki; Gtavriilidis, George; Mentzelopoulos, Spyros D.; Nora, David; Boyd, Sean; Coelho, Luís; Maizel, Julien; Cheyron, Damien du; Imouloudene, Mehdi; Quenot, Jean‐Pierre; Guilbert, Arnaud; Cillóniz, Catia

doi:10.1007/s00134-021-06588-8

Cited by 5 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For these reasons, it is not surprising that some authors reported the significant increasing relevance of this pathogen in patients with SARS-CoV2 infection, particularly in those with prolonged mechanical ventilation, with evidence of increasing incidence of VAP [ 3 ].…”

Section: Discussionmentioning

confidence: 99%

“…A significant incidence of ventilator-associated pneumonia (VAP) has been reported in SARS-CoV2 patients admitted to the Intensive Care Unit (ICU) during the COVID-19 pandemic [ 1 ]. Some authors reported VAP incidence peaking at 40% with an incidence density of 28/1000 ventilator days [ 2 , 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, in this specific scenario of VAP superinfection in critically ill COVID-19 patients, several studies reported an unusually high incidence of Burkholderia cepacea and Stenotrophomonas maltophilia among gram-negative pathogens [ 2 ]. The prevalence of VAP due to multi-drug resistant (MDR) isolates varies from 23 to 35% with large differences among countries [ 3 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Ceftazidime/Avibactam in Ventilator-Associated Pneumonia Due to Difficult-to-Treat Non-Fermenter Gram-Negative Bacteria in COVID-19 Patients: A Case Series and Review of the Literature

et al. 2022

View full text Add to dashboard Cite

Ventilator-associated pneumonia (VAP) in critically ill patients with COVID-19 represents a very huge global threat due to a higher incidence rate compared to non-COVID-19 patients and almost 50% of the 30-day mortality rate. Pseudomonas aeruginosa was the first pathogen involved but uncommon non-fermenter gram-negative organisms such as Burkholderia cepacea and Stenotrophomonas maltophilia have emerged as other potential etiological causes. Against carbapenem-resistant gram-negative microorganisms, Ceftazidime/avibactam (CZA) is considered a first-line option, even more so in case of a ceftolozane/tazobactam resistance or shortage. The aim of this report was to describe our experience with CZA in a case series of COVID-19 patients hospitalized in the ICU with VAP due to difficult-to-treat (DTT) P. aeruginosa, Burkholderia cepacea, and Stenotrophomonas maltophilia and to compare it with data published in the literature. A total of 23 patients were treated from February 2020 to March 2022: 19/23 (82%) VAPs were caused by Pseudomonas spp. (16/19 DTT), 2 by Burkholderia cepacea, and 6 by Stenotrophomonas maltophilia; 12/23 (52.1%) were polymicrobial. Septic shock was diagnosed in 65.2% of the patients and VAP occurred after a median of 29 days from ICU admission. CZA was prescribed as a combination regimen in 86% of the cases, with either fosfomycin or inhaled amikacin or cotrimoxazole. Microbiological eradication was achieved in 52.3% of the cases and the 30-day overall mortality rate was 14/23 (60.8%). Despite the high mortality of critically ill COVID-19 patients, CZA, especially in combination therapy, could represent a valid treatment option for VAP due to DTT non-fermenter gram-negative bacteria, including uncommon pathogens such as Burkholderia cepacea and Stenotrophomonas maltophilia.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ceftazidime/Avibactam in Ventilator-Associated Pneumonia Due to Difficult-to-Treat Non-Fermenter Gram-Negative Bacteria in COVID-19 Patients: A Case Series and Review of the Literature

et al. 2022

View full text Add to dashboard Cite

show abstract

“…18,8 %, i Klebsiella spp. 11,5 % 9 . Govoreći o VAP-u kod kritično oboljelih bolesnika s COVID-om, nekoliko je studija izvijestilo o neobično visokoj učestalosti Burkholderia cepacia i Stenotrophomonas maltophilia među gram-negativnim patogenima 3 .…”

unclassified

“…Govoreći o VAP-u kod kritično oboljelih bolesnika s COVID-om, nekoliko je studija izvijestilo o neobično visokoj učestalosti Burkholderia cepacia i Stenotrophomonas maltophilia među gram-negativnim patogenima 3 . Prevalencija VAP-a uzrokovanog organizmima otpornim na više antimikrobnih lijekova varira od 23 do 35 % s velikim razlikama među zemljama 9 . Smjernice Američkog društva za infektivne bolesti (engl.…”

unclassified

Ceftazidime/ Avibactam for Treatment of Intrahospital Ventilator-Associated Pneumonia in COVID-19 Patients

Mandarić,

Šitum,

Siroglavić

et al. 2024

Med. Flum. (Online)

View full text Add to dashboard Cite

U razdoblju pandemije koronavirusne bolesti 2019. (COVID-19) mnogi bolesnici kojima je bila potrebna invazivna mehanička ventilacija, primljeni su u jedinice intenzivnog liječenja (JIL) zbog teškog respiratornog zatajenja povezanog s bolešću COVID-19. Prijam u JIL i invazivna mehanička ventilacija neovisni su rizici za pneumoniju povezanu s ventilatorom (engl. ventilator associated pneumonia; VAP), kod koje je zabilježena visoka stopa smrtnosti i dulji boravak u JIL-u te je produljeno bolničko liječenje. Ako govorimo o uzročnicima VAP-a, Pseudomonas aeruginosa bio je jedan od glavnih gram-negativnih nefermentirajućih uzročnika ove patologije, zajedno s Burkholderia cepacia i Stenotrophomonas maltophilia u manjoj mjeri. Protiv gram-negativnih mikroorganizama otpornih na karbapeneme, ceftazidim/avibaktam (CZA) jedan je od najčešće korištenih antimikrobnih lijekova. Cilj ovog preglednog članka bio je opisati korištenje CZA u liječenju bolesnika s infekcijom COVID-19 koji su razvili VAP uzrokovan P. aeruginosa, B. cepacia i S. maltophilia, usporediti to s podatcima objavljenim u literaturi te skrenuti pozornost na kontinuiranu primjenu lijeka kao drugačijeg modaliteta u odnosu na standardni način primjene u bolusu. Unatoč visokoj smrtnosti kritično oboljelih bolesnika s COVID-om, CZA predstavlja valjanu opciju liječenja VAP-a uzrokovanog nefermentirajućim gram-negativnim mikroorganizmima.

show abstract

Implications of microscale lung damage for COVID-19 pulmonary ventilation dynamics: A narrative review

et al. 2021

View full text Add to dashboard Cite

The COVID-19 pandemic surges on as vast research is produced to study the novel SARS-CoV-2 virus and the disease state it induces. Still, little is known about the impact of COVID-19-induced microscale damage in the lung on global lung dynamics. This review summarizes the key histological features of SARS-CoV-2 infected alveoli and links the findings to structural tissue changes and surfactant dysfunction affecting tissue mechanical behavior similar to changes seen in other lung injury. Along with typical findings of diffuse alveolar damage affecting the interstitium of the alveolar walls and blood-gas barrier in the alveolar airspace, COVID-19 can cause extensive microangiopathy in alveolar capillaries that further contribute to mechanical changes in the tissues and may differentiate it from previously studied infectious lung injury. Understanding microlevel damage impact on tissue mechanics allows for better understanding of macroscale respiratory dynamics. Knowledge gained from studies into the relationship between microscale and macroscale lung mechanics can allow for optimized treatments to improve patient outcomes in case of COVID-19 and future respiratory-spread pandemics.

show abstract

Correction to: Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study

Cited by 5 publications

References 0 publications

Ceftazidime/Avibactam in Ventilator-Associated Pneumonia Due to Difficult-to-Treat Non-Fermenter Gram-Negative Bacteria in COVID-19 Patients: A Case Series and Review of the Literature

Ceftazidime/Avibactam in Ventilator-Associated Pneumonia Due to Difficult-to-Treat Non-Fermenter Gram-Negative Bacteria in COVID-19 Patients: A Case Series and Review of the Literature

Ceftazidime/ Avibactam for Treatment of Intrahospital Ventilator-Associated Pneumonia in COVID-19 Patients

Implications of microscale lung damage for COVID-19 pulmonary ventilation dynamics: A narrative review

Contact Info

Product

Resources

About